Activaero appoints chief business officer

Christian Pangratz takes the role

Activaero, a German leader in controlled breathing inhalation technologies and therapeutics, has appointed Christian Pangratz as chief business officer.

Pangratz joins Activaero from Nektar Therapeutics, in San Francisco, US, where he recently served as executive director of business development. He brings to Activaero 20 years of life science experience.

Pangratz will join the Activaero management team and lead all business development, marketing and alliance management activities. He replaces Henrik Luessen, who has decided to focus on his own consultancy firm, but will continue to support Activaero’s business development team on a part-time basis.

You may also like

Finance

Vectura Group to buy Activaero for £108m

Will enable Vectura to build a therapeutic specialist in airways diseases
Manufacturing

Valve diagnostics: providing new insights for medical and lab applications

Across a range of medical and laboratory applications, confirmation of liquid flow status is critical, but integrating sensors or electronics to check the performance of functions like valve switching adds design complexity
Manufacturing

Marchesini Group and AST announce strategic partnership to strengthen aseptic production capacity and expand global market presence

Marchesini Group, a leader in pharmaceutical packaging machinery, and AST, a US leader in the drug product manufacturing industry, have entered a strategic partnership that combines the expertise, technologies, and global reach of two highly respected industry leaders
Research & Development

New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research

Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Finished Product

New UK-developed blood test identifies breast cancer type without biopsy

A new ctDNA-based blood test offers near-90% accuracy in identifying and tracking breast cancer subtypes, opening opportunities for earlier treatment matching and more efficient therapy selection
Research & Development

Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery

The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Research & Development

PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific

The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape
Subscribe now